No widely recommended vaccine for feline infectious peritonitis (FIP) exists today. One commercially available intranasal vaccine, based on a temperature-sensitive strain of the virus, has been on the market since the 1990s, but major veterinary bodies generally do not recommend it for routine use. The reason traces to a frustrating immunological paradox: the very antibodies a vaccine generates can, under certain conditions, make the disease worse. That paradox has stalled vaccine development for decades, but the FIP landscape has changed dramatically in recent years thanks to antiviral drugs that can now cure what was once considered a death sentence.
Why FIP Is Uniquely Difficult to Vaccinate Against
FIP doesn’t start as FIP. Nearly all cats in multi-cat environments encounter feline coronavirus (FCoV), a common gut virus that usually causes mild or no symptoms. In a small percentage of infected cats, the virus mutates internally, gaining the ability to infect immune cells called macrophages and triggering a runaway inflammatory response. The mutated form is what veterinarians call feline infectious peritonitis virus (FIPV), and those mutations, concentrated in the spike protein, fundamentally change the virus’s behavior from harmless to lethal.1PubMed Central. Feline Coronaviruses: Pathogenesis of Feline Infectious Peritonitis
This creates a problem no other common vaccine faces. You’re not trying to prevent infection by an external pathogen in the usual sense. You’re trying to stop a virus the cat may already carry from mutating into something dangerous inside the cat’s own body. A traditional vaccine primes the immune system to recognize and destroy a specific invader, but FCoV is already a familiar resident of the gut in most shelter and cattery cats. The immune system has already met it. The challenge is preventing or controlling what happens when it changes.
Making matters worse, diagnostic tools can’t easily distinguish between the harmless gut coronavirus and its deadly mutant form. Many standard tests pick up both equally, which means it’s hard to know whether a vaccinated cat is protected or simply hasn’t yet had the bad luck of an internal mutation.2PubMed Central. Diagnosis of Feline Infectious Peritonitis: A Review of the Current Literature
The Antibody Problem That Haunts FIP Vaccines
The biggest obstacle to an FIP vaccine isn’t a lack of effort. It’s a phenomenon called antibody-dependent enhancement, or ADE. In most diseases, antibodies are your friend: they tag a pathogen so the immune system can destroy it. With FIP, certain antibodies against the virus’s spike protein can actually help the virus get inside macrophages more efficiently. Instead of neutralizing the virus, the antibodies act like a Trojan horse, escorting it into the very cells it wants to infect.
Research has shown that when cats carrying antibodies against one serotype of FIPV are re-exposed to the same serotype, the disease can develop faster and more severely than it would in a cat with no prior antibodies at all.3PubMed. Antibody-dependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection This is the nightmare scenario for vaccine developers: a vaccine that teaches the immune system to produce exactly the wrong kind of response, potentially accelerating the disease it was meant to prevent.
Studies looking at the immune response during FIP development help explain why. As the disease progresses, the cat’s production of key immune-signaling molecules collapses. Researchers found that after an initial brief spike, levels of several critical immune messengers became markedly depressed, suggesting the virus effectively dismantles the immune system’s ability to coordinate a defense.4PubMed Central. Antibody and cytokine responses in kittens during the development of feline infectious peritonitis (FIP) A vaccine that boosts antibody production without fixing this broader immune dysfunction may do more harm than good.
The Existing Vaccine and Its Limits
The one vaccine that made it to market is an intranasal product based on a temperature-sensitive strain of the virus. The idea is clever: the modified virus can replicate in the cooler tissues of the nose and upper airways (stimulating a local immune response) but cannot survive at the warmer core body temperature, so it shouldn’t cause systemic disease. In laboratory trials, this approach worked reasonably well. In one controlled study, 85% of vaccinated cats survived a severe challenge dose that killed or sickened all unvaccinated controls.5Vaccine. Protection against feline infectious peritonitis by intranasal inoculation of a temperature-sensitive FIPV vaccine
An interesting detail from that trial: protection didn’t correlate with the level of antibodies in the blood. Vaccinated cats that survived actually had lower blood antibody levels than unvaccinated cats that got sick. What did correlate with survival was a mucosal IgA response, the type of immune defense that works at the body’s surfaces rather than in the bloodstream. This finding reinforced suspicions about ADE: high blood-antibody levels weren’t just unhelpful, they were a marker of the immune-mediated pathology driving FIP.
Field trials told a more complicated story. In a double-blind, placebo-controlled study across high-risk cat populations, the vaccine proved safe and showed efficacy in cats that had low or no antibodies against feline coronavirus at the time of vaccination. But some vaccinated cats that later developed FIP turned out to have already been carrying the virus in their blood at the time they received the shot. The vaccine couldn’t help cats that were already infected.6PubMed Central. Placebo-controlled evaluation of a modified life virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions
This is the crux of why the vaccine isn’t broadly recommended. In the real world, many of the cats most at risk for FIP (those in shelters, catteries, and multi-cat homes) have already been exposed to feline coronavirus by the time they’re old enough to vaccinate. The vaccine appears to help only a subset of cats: those that are truly coronavirus-naïve. For the majority of at-risk cats, the window has already closed.
How Antiviral Drugs Changed the Equation
While vaccine research stalled, a different approach emerged that has fundamentally altered how veterinarians and cat owners think about FIP. The drug GS-441524, a nucleoside analog that blocks the virus from replicating, has turned FIP from an invariably fatal diagnosis into a treatable one.
A systematic review covering studies from 2018 through 2024, encompassing 650 FIP cases, found an overall treatment success rate of about 85%. Success rates were higher when GS-441524 was combined with other antivirals, and lower in cats with the wet form of FIP or neurological involvement.7PubMed Central. Efficacy of GS-441524 for Feline Infectious Peritonitis: A Systematic Review (2018-2024) A large Iranian study of over 600 cats reported a survival rate above 94%, with a relapse rate under 1%.8PubMed Central. Analysis of risk factors, clinical data, treatment outcomes for cats with feline infectious peritonitis using GS-441524 (2020-2024)
FIP comes in two recognized clinical forms: the effusive (“wet”) form, marked by fluid buildup in the chest or abdomen, and the noneffusive (“dry”) form, characterized by inflammatory lesions in organs including the brain.9PubMed Central. Diagnosis and clinical signs of feline infectious peritonitis in the central nervous system Both forms respond to GS-441524, though neurological cases remain the hardest to treat because the drug needs to cross the blood-brain barrier at sufficient concentrations. Other antivirals, including oral remdesivir and molnupiravir as a rescue option for relapsed cases, are being explored as complements.10PubMed Central. Efficacy of oral remdesivir in treating feline infectious peritonitis: a prospective observational study of 29 cats
The practical impact of these drugs can’t be overstated. For years, an FIP diagnosis meant euthanasia was the only humane option. Now, with a treatment course that typically lasts about 12 weeks, the vast majority of treated cats recover. This shift has reduced some of the urgency around vaccination: if you can cure FIP, preventing every case becomes slightly less existentially critical, though prevention obviously remains the ideal.
Getting Hold of Treatment Isn’t Always Simple
Despite the strong clinical evidence, accessing GS-441524 has been a legal gray area in many countries. For years, the drug was not officially licensed for veterinary use, and veterinarians faced genuine professional risk in prescribing or endorsing it. A prospective study of cat owners using unlicensed GS-441524 found that many veterinary providers were hesitant to get involved, citing serious concerns about being affiliated with an unlicensed drug. Licensed veterinarians in some jurisdictions face legal restrictions that prevent them from prescribing or endorsing unlicensed medications, limiting their ability to support clients even when the evidence is overwhelming.11PubMed Central. Owner experience and veterinary involvement with unlicensed GS-441524 treatment of feline infectious peritonitis: a prospective cohort study
The regulatory landscape is shifting. In several countries, compounded or licensed formulations of GS-441524 have begun to reach the market through official veterinary channels. But the pace of regulatory approval hasn’t kept up with the pace of scientific evidence, which has created a situation where some owners source the drug through informal channels, often from overseas suppliers, and administer it with varying levels of veterinary oversight. If your cat is diagnosed with FIP, finding a veterinarian who is up to date on antiviral treatment options and willing to guide you through the process is one of the most important steps you can take.
mRNA Vaccines on the Horizon
Researchers haven’t given up on vaccination entirely. In fact, the technology that powered COVID-19 vaccines in humans may offer a way around the ADE problem that has plagued FIP vaccine efforts for decades.
The key insight behind a new approach is targeting a different viral protein altogether. Traditional FIP vaccine candidates targeted the spike protein, which is the same protein whose antibodies can trigger ADE. A recent study developed an mRNA vaccine encapsulated in lipid nanoparticles that instead encodes the nucleocapsid (N) protein, an internal structural protein that doesn’t sit on the virus surface and shouldn’t trigger the same enhancement effect. In a proof-of-concept study in mice, the vaccine stimulated both antibody responses and cytotoxic T cell activity against the target protein. A version of the mRNA optimized for stability showed improved protein production in feline cells in the lab.12PubMed Central. Feline Infectious Peritonitis mRNA Vaccine Elicits Both Humoral and Cellular Immune Responses in Mice
This is still early-stage research. The vaccine has only been tested in mice so far, and the researchers note it provides justification for beginning safety and efficacy trials in cats rather than offering a product ready for clinics. But the strategy is promising precisely because it sidesteps the fundamental immunological trap that derailed previous efforts. If a vaccine can train the immune system to attack the virus’s internal machinery through cell-mediated immunity rather than by producing spike-targeting antibodies, ADE becomes much less of a concern.
Which Cats Are Most at Risk
Even without an effective vaccine, understanding which cats face the greatest danger from FIP helps owners make informed decisions about monitoring and early intervention. Epidemiological data consistently points to a genetic component: certain breeds are significantly more susceptible. A large study found that Abyssinians, Bengals, Birmans, Himalayans, Ragdolls, and Rex breeds had a significantly higher risk of developing FIP, while Burmese, Exotic Shorthairs, Manx, Persians, Russian Blues, and Siamese cats were not at increased risk. Sexually intact cats and purebred cats in general were also more likely to be diagnosed, along with males and young cats.13PubMed Central. Prevalence of feline infectious peritonitis in specific cat breeds
Genome-wide studies have identified specific chromosomal regions associated with FIP susceptibility, with different genetic associations appearing in different age groups, suggesting that the mechanisms of natural resistance shift as cats mature.14PubMed Central. The influence of age and genetics on natural resistance to experimentally induced feline infectious peritonitis The broader takeaway is that FIP isn’t random bad luck: a cat’s genetic background meaningfully influences whether a routine feline coronavirus infection tips over into fatal disease.15PubMed Central. Genetic determinants of pathogenesis by feline infectious peritonitis virus
For breeders, this has practical implications. Repeated FIP cases in a breeding line may reflect genetic vulnerability, not just environmental exposure. While there’s no genetic test you can run to predict FIP with certainty, paying attention to lineage patterns and working with veterinarians who understand the breed-specific risks can inform breeding decisions.
Practical Prevention Without a Vaccine
Since vaccination isn’t a reliable option for most cats, prevention falls back on environmental management and reducing viral load. Feline coronavirus spreads primarily through the fecal-oral route: cats shed the virus in their feces, and other cats pick it up from shared litter trays. Reducing this exposure is the single most impactful thing you can do.
Research on litter management recommends that, where possible, cats be allowed outdoor access to defecate, or that each cat have its own separate litter tray.16PubMed Central. Effect of cat litters on feline coronavirus infection of cell culture and cats Regular cleaning, scooping at least once or twice daily, and periodically replacing litter trays entirely all reduce the amount of virus in the environment. In multi-cat households and catteries, keeping group sizes small limits transmission chains.
Reducing stress also matters, though quantifying its contribution is harder. Stress suppresses immune function in cats just as it does in humans, and events like rehoming, overcrowding, surgery, or the introduction of new cats can tip the balance in a cat that’s carrying the coronavirus without symptoms. Kittens are especially vulnerable because their immune systems are still developing, which is part of why FIP disproportionately strikes cats under two years old.
When Other Infections Complicate Things
FIP doesn’t always occur in isolation. Immunosuppressive retroviruses, particularly feline leukemia virus (FeLV), can worsen the picture. FeLV attacks the immune system directly, and when a cat is dealing with both FeLV and a feline coronavirus infection, the combined pathological impact is greater than either infection alone. Case studies have documented how the hematological abnormalities and organ damage in co-infected cats are more severe than in cats with just one of the two viruses.17ARSHI Veterinary Letters. Feline infectious peritonitis and feline leukemia virus co-infection: a case study on diagnostic and clinical pathological findings
Feline immunodeficiency virus (FIV) can similarly compromise a cat’s ability to mount an effective defense against coronavirus. This is where other vaccines do become relevant. While there’s no reliable FIP vaccine, keeping your cat up to date on its FeLV vaccination (which is effective and widely recommended for at-risk cats) removes one of the factors that can push a benign coronavirus infection toward FIP. Maintaining overall immune health through proper nutrition, parasite control, and veterinary care reduces the odds that a routine viral exposure spirals into something worse.
For owners of cats diagnosed with FIP who also test positive for a retrovirus, treatment decisions become more complicated. GS-441524 treats the coronavirus, but it doesn’t address the underlying immunosuppression from FeLV or FIV. Veterinarians managing these cases typically need to address both problems simultaneously, and outcomes may be less predictable than in cats with FIP alone.
What Breeders and Shelter Operators Should Watch For
In environments where many cats live together, feline coronavirus is essentially unavoidable. Seroprevalence in multi-cat settings can exceed 80%, meaning nearly every cat in a shelter or cattery has been exposed. Only a fraction of those cats will develop FIP, but the fraction is still devastating when you’re responsible for dozens or hundreds of animals.
Breeders with recurring FIP losses should consider whether the genetic lines they’re working with carry heightened susceptibility. The breed-specific risk data suggests this is more than theoretical. Beyond genetics, catteries can reduce risk through quarantine protocols for new arrivals, early weaning strategies that limit kitten exposure to viral shedding from queens, and aggressive litter hygiene. Some catteries have adopted the practice of separating kittens from the general population by five to six weeks of age and raising them in isolation to delay coronavirus exposure until their immune systems are more mature.
Shelter operators face a different calculus. They can’t select for genetics, and they often can’t provide the space or staffing for individualized litter management. For shelters, the most practical interventions are minimizing the length of stay (the longer a cat is in a shelter, the higher the likelihood of coronavirus exposure), keeping housing areas well ventilated, and training staff to recognize the early signs of FIP so that antiviral treatment can begin quickly. The availability of GS-441524 has given shelters a tool they never had before, though cost and regulatory access remain barriers.